Skip to Content

Atara Biotherapeutics, Inc.

Securities Class Action

  • Date:
  • 5/22/2026
  • Company Name:
  • Atara Biotherapeutics, Inc.
  • Stock Symbol:
  • ATRA
  • Class Period:
  • FROM 5/20/2024 TO 1/9/2026
  • Status:
  • Filed
  • Filing Date:
  • 3/23/2026
  • Court:
  • U.S. District Court: Central California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Atara securities between May 20, 2024 and January 9, 2026, both dates inclusive (the “Class Period”). Investors have until May 22, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Atara's business, operations, and prospects, including allegations that: (i) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel Biologics License Application; (ii) accordingly, tabelecleucel’s regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; and (iv) all the foregoing was likely to have a significant negative impact on Atara’s business and financial condition.

If you purchased or otherwise acquired Atara shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Atara Biotherapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: